Drug Profile
ALD 301
Alternative Names: ALD-301Latest Information Update: 31 Aug 2016
Price :
$50
*
At a glance
- Originator Aldagen
- Developer Aldagen; National Heart, Lung and Blood Institute; University of Texas Health Science Center at Houston
- Class Stem cell therapies
- Mechanism of Action Angiogenesis inducing agents; Cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Phase II Peripheral arterial occlusive disorders